



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: September 28, 2011

To: Primary Clinical Research Associates

From: Sanna McKinzie
Research Protocol Specialist

Re: N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

The Registration (Step 2) Eligibility Checklist has been revised as follows:

Form Title	Brief Description of Edit
Registration (Step 2) Eligibility Checklist	The following statement has been added to the Grouping Factor, Subgroup code, and Assigned Treatment sections: [Study 2, Group 1 (Arm B) only (CLOSED TO ACCRUAL AS OF 9/27/2011)].

If you have any questions, please feel free to contact me at 507/538-6646.

SM/dg
Enclosure